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Identity 
 
 
t(7;9)(q11;p13) RHG-banding (Courtesy Nicole Dastugue). 
Clinics and pathology 
Disease 
B-cell acute lymphoblastic leukemia (B-ALL). 
Phenotype / cell stem origin 
Pre-B3 phenotype (CD10+ Cmu+) and pre-B2 
phenotype (CD10+ Cmu-). 
Embryonic origin 
Only two cases described: a 38-year-old male patient 
and a 16-year-old male patient. 
Treatment 
GRAAL 2003 trial and LALA94 trial. 
Evolution 
Relapse post allograft for both patients. 
Prognosis 
Poor (16 months survival for both patients). 
Cytogenetics 
Probes 
BAC probes: RP11-243F8 for PAX5 and CTD-
2278A11 for ELN. 
Additional anomalies 
del(9)(p11p13) in 1 of 2 cases but without PAX5 
deletion. 
Genes involved and Proteins 
PAX5 
Location: 9p13 
DNA / RNA 
The PAX5 locus spans approximately 200 kb. PAX5 
contains 10 exons and two distinct promoters resulting 
in two alternative 5' exons (1a and 1b). PAX5b is 
transcribed in the central nervous system and testis as 
well as in the B lymphoid lineage. PAX5a, also named 
B-cell specific activator protein (BSAP), is specifically 
transcribed in the B lymphoid lineage. 
Protein 
PAX5 is a member of the highly conserved paired box 
(PAX)-domain family of transcription factors. The 
PAX5 plays an important role in cell differentiation and 
in embryonic development. PAX5 is expressed from 
early stages of B-cell development up to mature B-cells 
and is down-regulated during terminal differentiation 
into plasma cells. PAX5 contains a paired box domain 
(DNA binding domain), a conserved octapeptide motif 
and a partial homeodomain. Its C-terminal region 
contains a transcriptional activation domain and the 
extreme C-terminal region acts as a repression domain. 
ELN 
Location: 7q11 
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DNA / RNA 
ELN locus spans approximately 40 kb and contains 33 
exons. 
Protein 
ELN is a 72-kDa insoluble extracellular matrix protein. 
Results of the chromosomal 
anomaly 
Hybrid gene 
Description 
5’PAX5-3’ELN, PAX5 exon 7 is fused in frame with 
ELN exon 2. 
Transcript 
The same PAX5-ELN transcript was amplified for both 
patients. Of note, the two alternative transcripts 
PAX5a-ELN and PAX5b-ELN were presents. The 
reciprocal ELN-PAX5 fusion transcript could not be 
amplified. 
 
 
Detection protocole 
The fusion transcript can be detected by RT-PCR using 
the 5' PAX5 sense primer: 5'-
CCCTGTCCATTCCATCAAGTCCTG-3’ and the 3' 
ELN antisense primer 5’-
ATGAGGTCGTGAGTCAGGGGTC-3’. 
Fusion protein 
Description 
The PAX5-ELN fusion protein conserves the DNA 
binding domain of PAX5 and its NLS, but looses its 
transactivation and repression domain. The quasi entire 
sequence of ELN is preserved without its signal 
peptide. 
Expression localisation 
 In HeLa cells transfected with the construction PAX5-
ELN, the chimera is localized in the nucleus. 
Oncogenesis 
PAX5-ELN acts as a dominant negative on wild-type 
PAX5 in in vitro experiments that could explain the 
blockade of differentiation in leukemic cells. 
 
 
 
Schematic representation of PAX5-ELN chimera. (A) Sequence of the in-frame fusion between exon 7 of PAX5 and exon 2 of ELN. (B) 
Structure of PAX5, PAX5-ELN and ELN proteins. PBD, Paired box domain; OCT, octapeptide; NLS, nuclear localization sequence; TD, 
transactivation domain; RD, repressor domain. 
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